Ticagrelor
- Generic Name
- Ticagrelor
- Brand Names
- Brilinta, Brilique
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28F2N6O4S
- CAS Number
- 274693-27-5
- Unique Ingredient Identifier
- GLH0314RVC
- Background
Ticagrelor, or AZD6140, was first described in the literature in 2003. Ticagrelor is an ADP derivative developed for its P2Y receptor antagonism. Unlike clopidogrel, ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,.
Ticagrelor was granted EMA approval on 3 December 2010.
Ticagrelor was granted FDA approval on 20 July 2011.
- Indication
Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
- Associated Conditions
- Cardiovascular Mortality, Myocardial Infarction, Stroke, Thrombosis (Stent Thrombosis)
- Associated Therapies
- -
Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Collegium Medicum w Bydgoszczy
- Target Recruit Count
- 73
- Registration Number
- NCT02602444
- Locations
- 🇵🇱
Cardiology Department, Dr. A. Jurasz University Hospital, Bydgoszcz, Kujawsko-pomorskie, Poland
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT02587260
- Locations
- 🇨🇭
Inselspitäl University Medical Center, Bern, Switzerland
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇮🇹Policlinico San Matteo, Pavia, Italy
The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Michael Wolzt, Prof. MD
- Target Recruit Count
- 24
- Registration Number
- NCT02580149
- Locations
- 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria
COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS
- Conditions
- Interventions
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Shenyang Northern Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02578537
- Locations
- 🇨🇳
Shenyang Northern Hospital, Shenyang, Liaoning, China
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
- Conditions
- Interventions
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 130
- Registration Number
- NCT02545933
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 101
- Registration Number
- NCT02539160
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Target Recruit Count
- 38
- Registration Number
- NCT02531165
- Locations
- 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland
Use of Ticagrelor in Korean ACS Patients: The BRILIANT KOREA Registry
- Conditions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT02521038
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts
- Conditions
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- University Hospital of Ferrara
- Target Recruit Count
- 44
- Registration Number
- NCT02519608
- Locations
- 🇮🇹
University Hospital of Ferrara, Cona, Ferrara, Italy
Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Yongjian Wu
- Target Recruit Count
- 60
- Registration Number
- NCT02513004
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.